Investment Analysts’ Weekly Ratings Changes for Elanco Animal Health (ELAN)
by Doug Wharley · The Cerbat GemElanco Animal Health (NYSE: ELAN) has recently received a number of price target changes and ratings updates:
- 1/11/2026 – Elanco Animal Health was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
- 1/3/2026 – Elanco Animal Health was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
- 12/29/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/22/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/20/2025 – Elanco Animal Health was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
- 12/18/2025 – Elanco Animal Health had its price target raised by analysts at Morgan Stanley from $18.00 to $22.00. They now have an “equal weight” rating on the stock.
- 12/15/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/10/2025 – Elanco Animal Health had its “overweight” rating reaffirmed by analysts at KeyCorp.
- 12/9/2025 – Elanco Animal Health is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $30.00 price target on the stock.
- 12/8/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/8/2025 – Elanco Animal Health was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
- 12/1/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/25/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/21/2025 – Elanco Animal Health is now covered by analysts at KeyCorp. They set an “overweight” rating and a $27.00 price target on the stock.
- 11/20/2025 – Elanco Animal Health was upgraded by analysts at KeyCorp to a “strong-buy” rating.
- 11/19/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/19/2025 – Elanco Animal Health was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $25.00 price target on the stock.
- 11/15/2025 – Elanco Animal Health was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
- 11/13/2025 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
Insider Buying and Selling
In other news, CFO Robert M. Vanhimbergen purchased 6,950 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer directly owned 124,233 shares in the company, valued at approximately $2,688,402.12. This represents a 5.93% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey N. Simmons bought 22,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, with a total value of $478,500.00. Following the purchase, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 43,450 shares of company stock valued at $937,883 over the last ninety days. 0.89% of the stock is currently owned by company insiders.
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.